AIM ImmunoTech Announces Release of the Next CEO Corner Segment
18 avr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
17 avr. 2024 03h00 HE
|
Sound Bioventures
Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolytics...
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
17 avr. 2024 03h00 HE
|
Theolytics
Oxford, UK April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a...
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
16 avr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
12 avr. 2024 08h00 HE
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Oncocyte Reports Full Year 2023 Financial Results
12 avr. 2024 06h00 HE
|
OncoCyte Corporation
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
11 avr. 2024 21h46 HE
|
OncoCyte Corporation
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
11 avr. 2024 17h30 HE
|
OncoCyte Corporation
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
11 avr. 2024 11h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...